BHVN

Biohaven Ltd. NYSE

Healthcare ·Biotechnology ·US · biohaven.com

$9.71

Mkt Cap $1.0B

52w Low $7.48 15.1% of range 52w High $22.22

50d MA $9.89 200d MA $12.24

P/E (TTM) -1.4x

EV/EBITDA -1.7x

P/B 19.9x

Debt/Equity 5.4x

ROE -1418.8%

P/FCF -2.0x

RSI (14) —

ATR (14) —

Beta 3.62

50d MA $9.89

200d MA $12.24

Avg Volume 2.2M

About

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 2, 2026	AMC	-1.22	-1.21	+0.8%	11.81	-3.2%	-9.7%	-10.2%	-12.7%	-16.0%	-13.5%	—
Nov 10, 2025	AMC	-1.91	-1.64	+14.1%	7.79	-0.8%	+9.4%	+2.1%	+3.7%	+6.5%	+6.2%	—
Aug 11, 2025	AMC	-1.94	-1.94	+0.0%	13.41	+1.9%	+0.4%	+7.3%	+6.1%	+17.2%	+19.4%	—
May 12, 2025	AMC	-1.67	-2.17	-29.9%	20.56	+0.9%	-5.1%	-4.4%	-23.1%	-22.1%	-23.4%	—
Mar 3, 2025	AMC	-1.56	-1.85	-18.6%	32.06	-1.4%	-2.2%	-3.4%	-5.2%	-6.9%	-13.8%	—
Nov 12, 2024	AMC	-1.70	-1.70	+0.0%	50.36	+2.9%	-2.6%	-3.4%	-11.9%	-9.8%	-8.1%	—
Aug 8, 2024	AMC	-1.72	-3.64	-111.6%	36.62	-1.3%	+6.3%	+1.0%	+7.3%	+4.1%	+7.2%	—
May 9, 2024	AMC	-1.50	-2.20	-46.7%	41.36	-3.0%	-13.7%	-18.3%	-10.0%	-10.3%	-7.0%	—
Feb 29, 2024	AMC	-1.41	-1.81	-28.4%	48.14	-1.4%	+2.9%	+17.1%	+21.8%	+20.8%	+20.6%	—
Nov 14, 2023	AMC	-1.33	-1.50	-12.8%	29.78	-0.5%	-2.5%	-0.4%	+1.0%	+2.8%	-0.8%	—
Jul 31, 2023	AMC	-1.24	-1.32	-6.5%	19.88	-0.9%	-1.2%	-3.0%	-3.7%	-1.0%	-3.3%	—
May 12, 2023	AMC	-1.39	-1.03	+25.9%	13.61	+1.5%	+6.9%	+1.9%	+3.7%	+1.9%	+3.6%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 2	Citigroup	Maintains	Buy → Buy	—	$9.62	$9.54	-0.8%	+1.9%	-4.9%	-3.7%	-2.5%	-2.4%
Mar 11	TD Cowen	Maintains	Buy → Buy	—	$10.27	$10.58	+3.0%	+1.9%	-3.5%	-6.7%	-6.1%	-7.2%
Mar 4	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$10.67	$10.76	+0.8%	-0.6%	-3.4%	-7.0%	-4.3%	-3.7%
Mar 3	RBC Capital	Maintains	Outperform → Outperform	—	$11.81	$11.43	-3.2%	-9.7%	-10.2%	-12.7%	-16.0%	-13.5%
Jan 21	RBC Capital	Upgrade	Sector Perform → Outperform	—	$12.68	$13.85	+9.2%	+1.5%	+8.5%	+6.5%	+0.5%	-0.1%
Jan 6	Morgan Stanley	Maintains	Overweight → Overweight	—	$9.93	$9.96	+0.3%	-3.1%	+18.2%	+14.4%	+11.9%	+19.2%
Dec 26	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$10.81	$9.67	-10.5%	+3.1%	+6.8%	+7.7%	+4.4%	+0.3%
Dec 3	HC Wainwright & Co.	Downgrade	Buy → Neutral	—	$8.83	$8.50	-3.7%	+3.3%	+8.8%	+8.2%	+19.4%	+18.7%
Nov 26	UBS	Downgrade	Buy → Neutral	—	$9.41	$9.00	-4.4%	+0.7%	+6.6%	-1.0%	-6.2%	-3.1%
Nov 20	JP Morgan	Maintains	Overweight → Overweight	—	$9.46	$9.67	+2.2%	+1.8%	+2.4%	+2.3%	-0.5%	+0.2%
Nov 18	BTIG	Maintains	Buy → Buy	—	$8.27	$8.25	-0.2%	+14.3%	+14.4%	+16.4%	+17.2%	+17.0%
Nov 18	Morgan Stanley	Maintains	Overweight → Overweight	—	$8.27	$8.25	-0.2%	+14.3%	+14.4%	+16.4%	+17.2%	+17.0%
Nov 13	Citigroup	Maintains	Buy → Buy	—	$7.95	$7.84	-1.4%	+1.6%	+4.4%	+4.0%	+18.9%	+19.0%
Nov 6	Bernstein	Downgrade	Outperform → Market Perform	—	$8.34	$8.61	+3.2%	+2.3%	-1.0%	-6.6%	+2.2%	-4.7%
Nov 6	BTIG	Maintains	Buy → Buy	—	$8.34	$8.61	+3.2%	+2.3%	-1.0%	-6.6%	+2.2%	-4.7%
Nov 6	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$8.34	$8.61	+3.2%	+2.3%	-1.0%	-6.6%	+2.2%	-4.7%
Nov 5	William Blair	Downgrade	Outperform → Market Perform	—	$13.95	$8.40	-39.8%	-40.2%	-38.9%	-40.8%	-44.2%	-38.9%
Nov 5	TD Cowen	Maintains	Buy → Buy	—	$13.95	$8.40	-39.8%	-40.2%	-38.9%	-40.8%	-44.2%	-38.9%
Sep 16	UBS	Maintains	Buy → Buy	—	$13.74	$13.70	-0.3%	-1.8%	+7.0%	+13.0%	+4.2%	+8.1%
Aug 19	BTIG	Maintains	Buy → Buy	—	$16.01	$15.89	-0.7%	-4.7%	-8.2%	-8.3%	-2.5%	-6.7%
Aug 12	Baird	Maintains	Outperform → Outperform	—	$13.41	$13.66	+1.9%	+0.4%	+7.3%	+6.1%	+17.2%	+19.4%
Aug 12	Morgan Stanley	Maintains	Overweight → Overweight	—	$13.41	$13.66	+1.9%	+0.4%	+7.3%	+6.1%	+17.2%	+19.4%
Aug 12	Leerink Partners	Maintains	Outperform → Outperform	—	$13.41	$13.66	+1.9%	+0.4%	+7.3%	+6.1%	+17.2%	+19.4%
Aug 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.41	$13.66	+1.9%	+0.4%	+7.3%	+6.1%	+17.2%	+19.4%
Aug 12	BofA Securities	Maintains	Buy → Buy	—	$13.41	$13.66	+1.9%	+0.4%	+7.3%	+6.1%	+17.2%	+19.4%
Jun 18	JP Morgan	Maintains	Overweight → Overweight	—	$14.56	$14.58	+0.1%	-1.2%	-0.7%	-0.7%	+1.4%	-1.6%
May 19	RBC Capital	Downgrade	Outperform → Sector Perform	—	$16.02	$15.45	-3.6%	-1.7%	+1.4%	-2.0%	-3.7%	-2.4%
May 13	RBC Capital	Maintains	Outperform → Outperform	—	$20.56	$20.75	+0.9%	-5.1%	-4.4%	-23.1%	-22.1%	-23.4%
Apr 28	Baird	Maintains	Outperform → Outperform	—	$19.84	$19.84	+0.0%	+9.6%	+10.3%	+11.5%	+13.2%	+15.2%
Mar 7	Morgan Stanley	Maintains	Overweight → Overweight	—	$30.40	$30.40	+0.0%	-1.8%	-9.1%	-3.3%	-3.3%	-7.2%
Mar 5	JP Morgan	Maintains	Overweight → Overweight	—	$31.37	$31.87	+1.6%	-1.3%	-3.1%	-4.8%	-11.9%	-6.2%
Mar 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$32.06	$31.61	-1.4%	-2.2%	-3.4%	-5.2%	-6.9%	-13.8%
Mar 4	RBC Capital	Maintains	Outperform → Outperform	—	$32.06	$31.61	-1.4%	-2.2%	-3.4%	-5.2%	-6.9%	-13.8%
Dec 17	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$41.44	$40.98	-1.1%	-5.6%	-13.1%	-14.7%	-12.5%	-12.8%
Dec 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$41.44	$40.98	-1.1%	-5.6%	-13.1%	-14.7%	-12.5%	-12.8%
Dec 4	RBC Capital	Maintains	Outperform → Outperform	—	$43.68	$43.95	+0.6%	+5.4%	-0.4%	+2.6%	-1.0%	-2.5%
Nov 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$45.23	$45.45	+0.5%	+4.5%	+2.5%	+1.7%	-1.1%	-3.4%
Nov 25	RBC Capital	Maintains	Outperform → Outperform	—	$45.59	$40.80	-10.5%	-0.8%	+3.7%	+1.7%	+0.9%	-1.9%
Nov 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$49.04	$48.98	-0.1%	-0.8%	-9.5%	-7.4%	-5.6%	-4.5%
Nov 13	TD Cowen	Maintains	Buy → Buy	—	$50.36	$51.81	+2.9%	-2.6%	-3.4%	-11.9%	-9.8%	-8.1%
Nov 13	RBC Capital	Maintains	Outperform → Outperform	—	$50.36	$51.81	+2.9%	-2.6%	-3.4%	-11.9%	-9.8%	-8.1%
Aug 13	UBS	Maintains	Buy → Buy	—	$36.97	$37.00	+0.1%	+6.3%	+3.1%	+6.2%	+4.4%	+7.5%
Jun 18	RBC Capital	Maintains	Outperform → Outperform	—	$32.99	$33.22	+0.7%	-0.7%	+1.4%	+1.7%	+5.3%	+6.1%
May 30	HC Wainwright & Co.	Maintains	Buy → Buy	—	$33.17	$33.49	+1.0%	+6.2%	+5.8%	+4.3%	+0.7%	+4.9%
May 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$35.69	$35.46	-0.6%	-5.4%	+4.3%	+3.9%	+7.7%	+4.7%
Apr 23	UBS	Maintains	Buy → Buy	—	$38.33	$40.54	+5.8%	+3.3%	+1.0%	+0.5%	+1.7%	+3.9%
Apr 9	RBC Capital	Maintains	Outperform → Outperform	—	$51.41	$51.62	+0.4%	+1.1%	-0.7%	+4.0%	+3.2%	-12.9%
Mar 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$49.54	$51.50	+4.0%	+13.8%	+18.4%	+17.3%	+17.2%	+17.0%
Mar 1	RBC Capital	Maintains	Outperform → Outperform	—	$48.14	$47.48	-1.4%	+2.9%	+17.1%	+21.8%	+20.8%	+20.6%
Mar 1	TD Cowen	Maintains	Outperform → Outperform	—	$48.14	$47.48	-1.4%	+2.9%	+17.1%	+21.8%	+20.8%	+20.6%

Recent Filings

8-K

Biohaven Ltd. -- 8-K Filing

Biohaven's experimental drug BHV-1300 demonstrated potent IgG reduction up to 87% in early testing, positioning the company to advance a pivotal Graves' disease trial in late 2026.

Mar 2

Data updated apr 24, 2026 9:36pm · Source: massive.com